Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 6597387, 8 pages
https://doi.org/10.1155/2018/6597387
Research Article

Copeptin as a Prognostic Marker in Acute Chest Pain and Suspected Acute Coronary Syndrome

12nd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, M. Skłodowskiej-Curie 10, 41-800 Zabrze, Poland
2Department of Cardiology, Tuen Mun Hospital, 23 Tsing Chung Koon Rd, Tuen Mun, Hong Kong
3Department of Accident and Emergency, Tuen Mun Hospital, 23 Tsing Chung Koon Rd, Tuen Mun, Hong Kong
4Department of Cardiology, Lausanne University Hospital, rue du Bugnon 46, 1011 Lausanne, Switzerland

Correspondence should be addressed to Beata Morawiec; lp.pw@ceiwaromaeb

Received 7 June 2017; Revised 25 August 2017; Accepted 18 October 2017; Published 24 January 2018

Academic Editor: Salvatore Di Somma

Copyright © 2018 Beata Morawiec et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. In patients admitted with chest pain and suspected acute coronary syndrome (ACS), it is crucial to early identify those who are at higher risk of adverse events. The study aim was to assess the predictive value of copeptin in patients admitted to the emergency department with chest pain and nonconclusive ECG. Methods. Consecutive patients suspected for an ACS were enrolled prospectively. Copeptin and high-sensitive troponin T (hs-TnT) were measured at admission. Patients were followed up at six and 12 months for the occurrence of death and major adverse cardiac and cerebrovascular events (MACCE). Results. Among 154 patients, 11 patients died and 26 experienced MACCE. Mortality was higher in copeptin-positive than copeptin-negative patients with no difference in the rate of MACCE. Copeptin reached the AUC 0.86 (0.75–0.97) for prognosis of mortality at six and 0.77 (0.65–0.88) at 12 months. It was higher than for hs-TnT and their combination at both time points. Copeptin was a strong predictor of mortality in the Cox analysis (HR14.1 at six and HR4.3 at 12 months). Conclusions. Copeptin appears to be an independent predictor of long-term mortality in a selected population of patients suspected for an ACS. The study registration number is ISRCTN14112941.